Subjects will be treated until they experience progressive disease, unacceptable toxicity, withdraw consent , or if the investigator feels it is no longer in their best interest to continue treatment. Duration of Follow -up: After discontinuation or completion of the study, subjects will be followed every 3 months for 18 months to collect follow -up information, including survival status and any current cancer treatment regimen. Reference Therapy, Dosage, and Mode of Administration: Not applicable. Confidential and Proprietary 11 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 Evaluation of Endpoints: Safety: Safety endpoints include assessments of treatment -emergent AEs, SAEs, and clinically significant changes in safety laboratory tests, physical examinations, ECGs, and vital signs. All subjects will be evaluable for toxicity from the time of their first study treatment.